Genetic counselors are trying once again to gain Medicare recognition through this bill, so they can bill for their services.
Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...
Tecentriq, Avastin Regimen Beats Anti-PD-L1 Monotherapy in MMR-Deficient, MSI-High Colorectal Cancer
Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...
CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...
The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.
So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.
The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.
The startup aims to create a platform for treating extremely rare genetic mutations, armed with CRISPR advances and new regulatory pathways.
Jazz Pharma to Submit Ziihera Data in First-Line HER2-Positive Gastroesophageal Cancer to Regulators
In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.
Axovia Therapeutics Nabs $1.1M Grant to Advance BBS1 Vision Loss Gene Therapy Toward Clinical Trials
With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback